The Cyprus IP Box for pharma, biotech & life sciences
Assess life-sciences IP Box eligibility by identifying the protected right, development history and net income attributable to it.
Why pharma & biotech companies qualify
Regulation 3 includes patents, specified patent-protection extensions, orphan-drug designations and legally protected plant or genetic rights. Confirm the precise right, its protection and the taxpayer’s ownership; a regulatory approval or scientific result alone does not establish every condition for relief.
- Patents, SPCs, orphan-drug designations and genetic/plant IP qualify.
- Using an overseas developer does not automatically disqualify expenditure from the Cyprus IP Box nexus. The regulations distinguish unrelated-party R&D from related-party outsourcing. You must still establish qualifying development, the asset connection, rights and costs, while examining cross-border tax and employment issues separately.
Illustration at full nexus
~3%
15% × 20% = 3% on qualifying net IP income at full nexus, before other adjustments. A lower nexus raises the effective rate.
Estimate your rate →Which life-sciences income qualifies
Licence fees and the supported IP contribution within product sales require attribution of income and related costs. Patent protection does not make the entire manufacturing or distribution margin qualifying profit.
Royalties & licence fees
Payments to use your patents, formulations or processes.
IP embedded in product price
The share of a product's price reflecting your patented IP.
Gains on IP disposal
Determine whether the disposal is capital or trading in nature. A genuine capital disposal of qualifying IP can receive different treatment from a trading sale, whose income may enter the IP Box calculation. A sale of shares is a separate transaction. Do not assume every software disposal is tax-free.
Pure resale or unrelated trading income does not qualify, and marketing IP (brands, trademarks) is always excluded.
Built for life sciences
Pharma & drug development
APIs, formulations, methods of use and orphan drugs.
Biotech & genetics
Genetic material, plant-variety rights and bio-processes.
Medical devices
Patented devices and the software embedded in them.
Diagnostics & healthtech
Proprietary diagnostics and protected healthtech IP.
Which life-sciences income qualifies
A worked example shows the effect. Assume €1,000,000 of qualifying profit from a patented product and a nexus ratio of 100%. The 80% notional deduction removes €800,000, leaving €200,000 taxable. At the 2026 corporate rate of 15%, tax due is €30,000 which is an effective rate of 3% on the IP profit.
Clinical & outsourced R&D and your nexus ratio
QE is qualifying R&D, A is acquisition cost and R is related-party R&D. OE = QE + A + R. UE = min(30% × QE, A + R). Nexus = min(1, (QE + UE) / OE), where OE is positive. Use the asset’s relevant historical expenditure; the denominator is not every accounting expense.
Developing a product internally does not replace the expenditure calculation. Use the relevant asset history, distinguish acquisition and related-party costs, and apply the capped uplift. Missing records or a zero denominator cannot be treated as full nexus.
Documentation for life-sciences IP
Connect patent and regulatory records to contracts, development work and asset-level income and expenditure. Explain outsourced clinical work and allocations so a reviewer can reconstruct the claim.
- Full development history for each qualifying asset.
- Records of who performed the R&D, in-house and via each CRO.
- Per-asset cost tracking splitting qualifying from non-qualifying spend.
- Trial and lab records retained as contemporaneous supporting evidence.
Pharma & biotech FAQ
Talk to a Cyprus IP Box specialist.
Book a free, no-obligation assessment. We'll confirm whether you qualify, estimate your effective rate, and give you a fixed quote — confidentially, usually within one business day.
IPBox Cyprus editorial team · Ebrovia Ltd · Updated September 27, 2026.
Sources & further reading
Related guides
- Cyprus IP Box Regime 2026: The Complete Guide
- Cyprus IP Box vs Other EU IP Boxes (2026 Comparison)
- The Cyprus IP Box for Startups: A Founder's Guide (2026)
- Does Software Qualify for the Cyprus IP Box? (2026 Guide)
- How the Cyprus IP Box is calculated: the nexus fraction explained (2026)
- How Much Does the Cyprus IP Box Cost? (2026)
- How Long Does the Cyprus IP Box Take? Timeline & the Tax Ruling (2026)
- Cyprus IP Box Requirements & Substance (2026)
- Cyprus IP Box versus Ireland KDB: eligibility, tax base and claim timing
- Cyprus Non-Dom Status & the 60-Day Rule Explained (2026)
- Cyprus corporate tax 2026 reform: what changed (and what it means for IP)
- Cyprus IP Holding Company: Structure & Tax (2026)
- Cyprus IP Box for AI and machine-learning businesses